# Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

> **NCT02172235** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Pioglitazone - low dose
- **DRUG:** BI 10773 - low dose
- **DRUG:** BI 10773 - medium dose
- **DRUG:** BI 10773 - high dose

## Key facts

- **NCT ID:** NCT02172235
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172235, "Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02172235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*